ISRG Research Update — August 28, 2026
Updated Thesis
Intuitive Surgical is a leading medical technology company specializing in robotic-assisted surgical systems, primarily the da Vinci Surgical System, and the Ion endoluminal system for lung biopsies. The company has a strong competitive moat due to its pioneering position, extensive installed base, and recurring revenue from instruments and services. In the most recent quarter, revenue grew 18.5% year-over-year and earnings grew 24.3%, reflecting robust demand.
The investment grade as of this refresh is B — solid business quality. High-tier business, fair-tier valuation
Key Metrics at a Glance
- Revenue growth: +18.5% year over year
- Net margin: 28.4%
- Fair value upside: +21.4% to our estimate of $446
Current price: $367.07
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Intuitive Surgical, Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full ISRG research →](/stocks/ISRG)